Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_provenance.
- NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_assertion description "[To identify the promising alternative approach, we investigated the therapeutic potential of targeting the interleukin (IL)-8/CXCR2 pathway in colon cancer treatment using both loss-of-function (CXCR2 knockout) and gain-of-function (IL-8 overexpression) mouse models, as the IL-8/CXCR2 pathway has been shown to be activated in intestinal tumors of both human and experimental animals.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_provenance.
- NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_assertion evidence source_evidence_literature NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_provenance.
- NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_assertion SIO_000772 24338666 NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_provenance.
- NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_assertion wasDerivedFrom befree-20150227 NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_provenance.
- NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_assertion wasGeneratedBy ECO_0000203 NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_provenance.
- befree-20150227 importedOn "2015-02-27" NP500800.RA9ZUM_n6h2vkGPDPhWQKs3soW_F7gE49JPtYobSLE4-I130_provenance.